retatrutide fda approval status november 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and fda glp-1 compounding enforcement november

Astaxanthin: A powerful antioxidant derived from microalgae, it reduces oxidative stress and supports skin hydration and elasticity

Many women ask if GLP-1s are safe to take postpartum as a way to get back to their pre-pregnancy weight

Many products are research-grade and may lack consistent quality standards

Head-to-head data from the SURMOUNT trials showed tirzepatide producing slightly greater weight loss at equivalent treatment durations

Furthermore, biomarkers of severe oxidative stress, such as 15-F2t-isoprostane, were significantly reduced in the supplemented group, proving that the extract was actively protecting the vascular walls from free radical damage

The study was conducted in accordance with the local legislation and institutional requirements